Elsevier Inc.

SHERPA: Unknown

People

  1. Mauro
    Mauro
  2. De Angelis
    De Angelis
  3. Geyer
    Geyer
  4. Park
    Park
  5. Sadelain
    Sadelain
  6. Scheinberg
    Scheinberg
  7. Wang
    Wang

Groups

  1. Adult Leukemia (10)
  2. Center for Hematologic Malignancies (10)
  3. Department of Medicine (10)
  4. Hematologic Malignancies, Division of (10)
  5. GSK Faculty (2)
  6. Hematologic Malignancies Research (2)
  7. Molecular Pharmacology and Chemistry Program Faculty (2)
  8. Sloan Kettering Institute Faculty (2)
  9. Tow Center for Developmental Oncology (TCDO) (2)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
Search Within
  1. "Clinical Lymphoma, Myeloma and Leukemia"
  2. "Adult Leukemia"
  3. "2016"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (3)
Groups
  1. Adult Leukemia (10)
  2. Center for Hematologic Malignancies (10)
  3. Department of Medicine (10)
  4. Hematologic Malignancies, Division of (10)
  5. GSK Faculty (2)
  6. Hematologic Malignancies Research (2)

More Groups

People
  1. Michael Mauro (6)
  2. Martin Tallman (2)
  3. Aaron Chang (1)
  4. Brigitte Senechal (1)
  5. Catherine Coombs (1)
  6. David Scheinberg (1)

More People

Years
  1. 2016 (10)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial: CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M.; Park, J.; RivieĢ€re, I.; Senechal, B.; Hsu, M.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Final phase IIa study results evaluating the CXCR4 antagonist BL-8040 in combination with cytarabine (Ara-C) for the treatment of relapsed/refractory AML patients
    Meeting Abstract

    Borthakur, G.; Tallman, M.; Ofran, Y.; Foran, J.; Uy, G.; DiPersio, J.; Nagler, A.; Rowe, J.; Showel, M.; Altman, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • A chart review of lower dosing of ponatinib in patients with chronic myeloid leukemia (CML): Preliminary findings
    Meeting Abstract

    Mauro, M.; McGarry, L.; Inguilizian, A.; du Moulin, R.; Huang, H.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • The PACE clinical trial vs the real-world: Comparison of ponatinib prescribing and duration of therapy in chronic-phase chronic myeloid leukemia (CP-CML) patients
    Meeting Abstract

    Mauro, M.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Rapid achievement of MR(4.5) after switching from imatinib to nilotinib in patients with chronic myeloid leukemia in chronic phase (CML-CP): Preliminary results from ENESTgoal
    Meeting Abstract

    Ritchie, E.; Deininger, M.; Erba, H.; Savona, M.; Paley, C.; Dautaj, I.; Mauro, M.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes
    Meeting Abstract

    Mathias, M.; Sockolosky, J.; Chang, A.; Liu, C.; Garcia, K.; Scheinberg, D.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Ponatinib therapy for Philadelphia-positive ALL (Ph+ ALL) patients: Real-world clinical practice vs the PACE trial
    Meeting Abstract

    Mauro, M.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia
    Journal Article

    Khoury, H. J.; Goldberg, S. L.; Mauro, M. J.; Stone, R. M.; Deininger, M. W.; Bradley-Garelik, M. B.; Mohamed, H.; Guilhot, F.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study
    Journal Article

    Cortes, J. E.; Lipton, J. H.; Miller, C. B.; Busque, L.; Akard, L. P.; Pinilla-Ibarz, J.; Keir, C.; Warsi, G.; Lin, F. P.; Mauro, M. J.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Pseudotumor cerebri in acute promyelocytic leukemia patients on Intergroup Protocol 0129: Clinical description and recommendations for new diagnostic criteria
    Journal Article

    Coombs, C. C.; De Angelis, L. M.; Feusner, J. H.; Rowe, J. M.; Tallman, M. S.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save